Halozyme Therapeutics Stock News & Updates
[WKN: A0DLHS | Symbol: HALO]
Biotech Stocks: AI Will Trigger Innovation-Driven Growth - Here are Three Stocks at 52-Week Highs That Traders Can Now Pick Up!
With BB Biotech (Traderfox model portfolio) and Medpace (US model portfolio), we are already invested...
Halozyme Therapeutics: Record Quarter Driven by High Licensing Revenues for Subcutaneous Administration
Halozyme Therapeutics develops technologies such as the proprietary enzyme rHuPH20 (ENHANZE platform),...
Halozyme Therapeutics: Huge Deals & Forecast Upgrades Ignite the Stock
Massive forecast upgrade: A huge profit leap and new top annual targets after strong quarterly results...
Halozyme: The “Toll Operator” of the Biotech World
Cash flow instead of research risk: Thanks to a unique licensing model, Halozyme benefits from the...
Halozyme Therapeutics - ENHANZE Licensing Revenues Boost Results Significantly!
Business drivers: The US biotech company Halozyme Therapeutics (HALO) specializes in products related...
Halozyme Therapeutics - ENHANZE Licensing Revenue Drives new Records in Revenue and Earnings!
Business Drivers: The US biotech company Halozyme Therapeutics (HALO) specializes in products within...
Halozyme Reports Strong Quarterly Results and Raises Full-Year Outlook - Stock with Up-Gap!
Halozyme is a biopharmaceutical technology company with a unique business model, as it does not develop...
Halozyme Therapeutics: Rapidly Rising Licensing Fees Make Halozyme a Biotech Top Pick
The stock of Halozyme was one of the first stocks I presented in this section on July 3, 2024. Shortly...
- ‹
- 1
- ›